Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

GoodRx Holdings (GDRX) Long-Term Debt Issuances (2020)

GoodRx Holdings' Long-Term Debt Issuances history spans 1 years, with the latest figure at $28.0 million for Q1 2020.

On a quarterly basis, Long-Term Debt Issuances changed N/A to $28.0 million in Q1 2020 year-over-year; TTM through Dec 2020 was $28.0 million, a N/A change, with the full-year FY2024 number at $472.0 million, changed N/A from a year prior.
Long-Term Debt Issuances hit $28.0 million in Q1 2020 for GoodRx Holdings.
Over the last five years, Long-Term Debt Issuances for GDRX hit a ceiling of $28.0 million in Q1 2020 and a floor of $28.0 million in Q1 2020.